GAMMA Investing LLC Raises Stock Holdings in Arvinas, Inc. (NASDAQ:ARVN)

GAMMA Investing LLC lifted its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 11,283.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,212 shares of the company’s stock after acquiring an additional 4,175 shares during the period. GAMMA Investing LLC’s holdings in Arvinas were worth $300,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ARVN. GF Fund Management CO. LTD. acquired a new stake in shares of Arvinas during the fourth quarter worth about $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Arvinas by 0.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after acquiring an additional 3,047 shares during the period. Voloridge Investment Management LLC acquired a new stake in Arvinas during the 4th quarter worth approximately $749,000. Woodline Partners LP grew its stake in shares of Arvinas by 39.2% in the 4th quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock valued at $13,280,000 after purchasing an additional 194,996 shares during the last quarter. Finally, Twinbeech Capital LP acquired a new position in shares of Arvinas in the fourth quarter valued at approximately $3,146,000. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Price Performance

ARVN opened at $7.44 on Friday. The company has a market capitalization of $543.05 million, a P/E ratio of -11.27 and a beta of 2.19. The firm’s fifty day moving average price is $7.46 and its two-hundred day moving average price is $12.93. Arvinas, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $34.11.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $2.07. Arvinas had a negative return on equity of 7.74% and a negative net margin of 10.92%. During the same quarter in the previous year, the firm earned ($0.97) earnings per share. The business’s revenue for the quarter was up 646.2% compared to the same quarter last year. On average, equities research analysts expect that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wells Fargo & Company lowered their target price on shares of Arvinas from $26.00 to $19.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Piper Sandler restated an “overweight” rating and issued a $14.00 price objective (down previously from $24.00) on shares of Arvinas in a research report on Friday, May 2nd. HC Wainwright set a $24.00 target price on Arvinas in a research report on Monday, June 2nd. Truist Financial reissued a “hold” rating and set a $11.00 target price (down from $21.00) on shares of Arvinas in a research note on Monday, May 5th. Finally, Guggenheim reduced their price target on Arvinas from $32.00 to $16.00 and set a “buy” rating for the company in a report on Friday, May 2nd. Ten analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $20.29.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.